Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in 2026 (ICBMT 2026) - Oct 8, 2026 - Abstract #SS08-1; Pres time: Sep 18, 2026; 04:50 PM - 05:20 PM; Location: Room D(2F); "In myelofibrosis, peri-transplant JAK1/2 inhibition (e.g., ruxolitinib) successfully dampens the systemic inflammatory cytokine storm, mitigating graft-versus-host disease (GvHD) risk while offering disease control...By pairing targeted niche-specific depletion with disease-tailored maintenance, these regimens can significantly lower non-relapse mortality while simultaneously addressing the biological drivers of disease recurrence. These potentially paradigm-shifting strategies require comparison with traditional conditioning intensity stratification schemes through randomized clinical trials to demonstrate their value for improving outcomes."
Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Leukemia • Mucositis • Myelofibrosis • Transplantation • FLT3 • JAK1 • KIT • PTPRC
|